Anastasios Karadimitris

List of Publications by Year
in descending order

74	2,585	218677	206112
papers	citations	26 h-index	48 g-index

76	76	76	5185
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. Haematologica, 2022, 107, 721-732.	3.5	17
2	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood, 2022, 139, 1939-1953.	1.4	15
3	Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
4	Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. Science Translational Medicine, 2021, 13, eabf0113.	12.4	32
5	Transitions in lineage specification and gene regulatory networks in hematopoietic stem/progenitor cells over human development. Cell Reports, 2021, 36, 109698.	6.4	38
6	Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. Nature Communications, 2021, 12, 5450.	12.8	19
7	Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression. , 2021, 9, e001519.		10
8	Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation inÂvitro. IScience, 2021, 24, 101989.	4.1	13
9	Interleukin 6â€blockade treatment for severe COVIDâ€19 in two patients with multiple myeloma. British Journal of Haematology, 2020, 190, e9-e11.	2.5	24
10	Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear. Cancer Cell, 2020, 37, 426-427.	16.8	23
11	Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia. Blood, 2020, 136, 1-2.	1.4	0
12	Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease. British Journal of Haematology, 2020, 191, 579-586.	2.5	6
13	Discovery of a CD10-negative B-progenitor in human fetal life identifies unique ontogeny-related developmental programs. Blood, 2019, 134, 1059-1071.	1.4	62
14	The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene, 2019, 38, 3216-3231.	5.9	33
15	Impaired cellular and humoral immunity is a feature of Diamondâ€Blackfan anaemia; experience of 107 unselected cases in the United Kingdom. British Journal of Haematology, 2019, 186, 321-326.	2.5	16
16	Invariant NKT cells as a platform for CAR immunotherapy and prevention of acute Graftâ€versusâ€Host Disease. HemaSphere, 2019, 3, 31-34.	2.7	6
17	Impact of route and adequacy of nutritional intake on outcomes ofÂallogeneic haematopoietic cell transplantation for haematologic malignancies. Clinical Nutrition, 2019, 38, 738-744.	5.0	37
18	Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment. Blood, 2019, 134, 4329-4329.	1.4	0

#	Article	IF	Citations
19	Câ€reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of earlyâ€and longâ€term mortality. British Journal of Haematology, 2018, 180, 889-892.	2.5	6
20	Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. Leukemia and Lymphoma, 2018, 59, 2040-2055.	1.3	10
21	Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. Cancer Cell, 2018, 34, 596-610.e11.	16.8	102
22	A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL). Blood, 2018, 132, 1682-1682.	1.4	12
23	High resolution IgH repertoire analysis reveals fetal liver as the likely origin of life-long, innate B lymphopoiesis in humans. Clinical Immunology, 2017, 183, 8-16.	3.2	15
24	The Role of Invariant NKT Cells in Immunity. , 2016, , 357-368.		0
25	The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. British Journal of Haematology, 2016, 173, 350-364.	2.5	21
26	Single-cell profiling of human megakaryocyte-erythroid progenitors identifies distinct megakaryocyte and erythroid differentiation pathways. Genome Biology, 2016, 17, 83.	8.8	124
27	Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. Blood Cancer Journal, 2016, 6, e500-e500.	6.2	9
28	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Blood, 2016, 128, 2226-2226.	1.4	1
29	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies. Blood, 2016, 128, 5223-5223.	1.4	6
30	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. Blood, 2016, 128, 3411-3411.	1.4	0
31	Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs. Blood, 2015, 125, 2553-2557.	1.4	33
32	Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97. Cell Death and Disease, 2015, 6, e2031-e2031.	6.3	28
33	Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure. EBioMedicine, 2015, 2, 642-648.	6.1	12
34	Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Therapeutic Advances in Hematology, 2015, 6, 128-141.	2.5	141
35	Myeloma Propagating Cells, Drug Resistance and Relapse. Stem Cells, 2015, 33, 3205-3211.	3.2	7
36	Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. Journal of Clinical Investigation, 2015, 125, 2279-2292.	8.2	39

#	Article	IF	Citations
37	Role and Regulation of CD1d in Normal and Pathological B Cells. Journal of Immunology, 2014, 193, 4761-4768.	0.8	33
38	Nuclear proteasomes carry a constitutive posttranslational modification which derails SDS-PAGE (but not CTAB-PAGE). Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 2222-2228.	2.3	4
39	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood, 2014, 123, 697-705.	1.4	184
40	Transcriptional and epigenetic basis for restoration of G6PD enzymatic activity in human G6PD-deficient cells. Blood, 2014, 124, 134-141.	1.4	24
41	Cell-typeâ€“specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPI deficiency. Blood, 2014, 124, 3151-3154.	1.4	3
42	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, 2013, 121, 318-328.	1.4	112
43	Mechanism of Polycomb recruitment to CpG islands revealed by inherited disease-associated mutation. Human Molecular Genetics, 2013, 22, 3187-3194.	2.9	6
44	Target enrichment and highâ€throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamondâ€Blackfan anaemia. British Journal of Haematology, 2013, 162, 530-536.	2.5	50
45	Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17579-17584.	7.1	138
46	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 5030-5036.	1.4	129
47	The Role of Invariant NKT Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Critical Reviews in Immunology, 2012, 32, 157-171.	0.5	9
48	Activated Invariant NKT Cells Regulate Osteoclast Development and Function. Journal of Immunology, 2011, 186, 2910-2917.	0.8	33
49	The Diagnostic Value of CD1d Expression in a Large Cohort of Patients With B-Cell Chronic Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2011, 136, 400-408.	0.7	25
50	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,. Blood, 2011, 118, 4052-4052.	1.4	0
51	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1945-1945.	1.4	0
52	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. Blood, 2010, 116, 2539-2539.	1.4	1
53	Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome. Blood, 2010, 116, 876-876.	1.4	1
54	Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma. Blood, 2010, 116, 4049-4049.	1.4	0

#	Article	IF	Citations
55	The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs). Blood, 2010, 116, 3576-3576.	1.4	0
56	Inherited GPI deficiency: A disorder of histone hypoacetylation. Birth Defects Research Part C: Embryo Today Reviews, 2009, 87, 327-334.	3.6	2
57	Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 874-880.	3.8	32
58	Regulation of multiple myeloma survival and progression by CD1d. Blood, 2009, 113, 2498-2507.	1.4	94
59	Targeted Therapy for Inherited GPI Deficiency. New England Journal of Medicine, 2007, 356, 1641-1647.	27.0	82
60	Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood, 2006, 107, 3138-3144.	1.4	33
61	Natural killer T cells and haemopoiesis. British Journal of Haematology, 2006, 134, 263-272.	2.5	3
62	Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nature Medicine, 2006, 12, 846-851.	30.7	196
63	Targeted Molecular Therapy for Inherited Glycosylphosphatidylinositol Deficiency.. Blood, 2006, 108, 487-487.	1.4	36
64	Human Invariant NKT Cells Are Required for Effective In Vitro Alloresponses. Journal of Immunology, 2005, 175, 5087-5094.	0.8	8
65	Defective Modification of Mannose Residues by Terminal Phosphoethanolamine Underlies Inherited GPI Deficiency.. Blood, 2005, 106, 128-128.	1.4	8
66	Regulation of Hematopoiesis In Vitro and In Vivo by Invariant NKT Cells.. Blood, 2005, 106, 2277-2277.	1.4	0
67	Evidence That Human NKT Cells Enhance Haemopoiesis through Recognition of CD1d Expressed in Haemopoietic Stem Cells with Long Term Clonogenic Capacity.. Blood, 2004, 104, 4129-4129.	1.4	4
68	Depletion of the CD1d-Restricted NKT Cells Suppresses In Vitro Alloreactivity: A Possible Means To Prevent aGVHD.. Blood, 2004, 104, 3069-3069.	1.4	0
69	Severe telomere shortening in patients with paroxysmal nocturnal hemoglobinuria affects both GPIâ€“ and GPI+ hematopoiesis. Blood, 2003, 102, 514-516.	1.4	23
70	Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. British Journal of Haematology, 2001, 115, 1010-1014.	2.5	49
71	The cellular pathogenesis of paroxysmal nocturnal haemoglobinuria. Leukemia, 2001, 15, 1148-1152.	7.2	60
72	Human CD1dâ€“glycolipid tetramers generated byin vitrooxidative refolding chromatography. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3294-3298.	7.1	168

#	Article	IF	Citations
73	Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood, 2000, 96, 2613-20.	1.4	35
74	Dyskeratosis and ribosomal rebellion. Nature Genetics, 1998, 19, 6-7.	21.4	65